Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes

Abstract Objective Diabetes has emerged as an important risk factor for mortality from COVID-19. Metformin, the most commonly prescribed glucose-lowering agent, has been proposed to influence susceptibility to and outcomes of COVID-19 via multiple mechanisms. We investigated whether, in patients with diabetes, metformin is associated with susceptibility to COVID-19 and its outcomes. Research Design and Methods We performed a propensity score–matched cohort study with active comparators using a large UK primary care dataset. Adults with type 2 diabetes patients and a current prescription for metformin and other glucose-lowering agents (MF+) were compared to those with a current prescription for glucose-lowering agents that did not include metformin (MF−). Outcomes were confirmed COVID-19, suspected/confirmed COVID-19, and associated mortality. A negative control outcome analysis (back pain) was also performed. Results There were 29 558 and 10 271 patients in the MF+ and MF− groups, respectively, who met the inclusion criteria. In the propensity score–matched analysis, the adjusted hazard ratios for suspected/confirmed COVID-19, confirmed COVID-19, and COVID-19-related mortality were 0.85 (95% CI 0.67, 1.08), 0.80 (95% CI 0.49, 1.30), and 0.87 (95% CI 0.34, 2.20) respectively. The negative outcome control analysis did not suggest unobserved confounding. Conclusion Current prescription of metformin was not associated with the risk of COVID-19 or COVID-19-related mortality. It is safe to continue prescribing metformin to improve glycemic control in patients with.

[1]  F. Ovalle,et al.  Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes , 2021, Frontiers in Endocrinology.

[2]  G. Gkoutos,et al.  Sodium‐glucose co‐transporter‐2 inhibitors and susceptibility to COVID‐19: A population‐based retrospective cohort study , 2020, Diabetes, obesity & metabolism.

[3]  Wei Zhang,et al.  Risk of Metformin in Patients With Type 2 Diabetes With COVID‐19: A Preliminary Retrospective Report , 2020, Clinical and translational science.

[4]  C. S. Kow,et al.  Mortality risk with preadmission metformin use in patients with COVID‐19 and diabetes: A meta‐analysis , 2020, Journal of medical virology.

[5]  B. Popkin,et al.  Individuals with obesity and COVID‐19: A global perspective on the epidemiology and biological relationships , 2020, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[6]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[7]  P. Ye,et al.  Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes , 2020, Cell Metabolism.

[8]  A. Kurniawan,et al.  Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection , 2020, Obesity Medicine.

[9]  K. Khunti,et al.  Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study , 2020, The Lancet Diabetes & Endocrinology.

[10]  F. Ovalle,et al.  METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES , 2020, medRxiv.

[11]  S. Jagannath,et al.  A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward , 2020, Journal of Hematology & Oncology.

[12]  K. Bhaskaran,et al.  OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[13]  D. Vojta,et al.  Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19 , 2020, medRxiv.

[14]  S. Jagannath,et al.  A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward , 2020, medRxiv.

[15]  S. Hadjadj,et al.  Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study , 2020, Diabetologia.

[16]  Dong Liu,et al.  Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis , 2020, The American journal of tropical medicine and hygiene.

[17]  Xuanzhe Zhang,et al.  Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study , 2020, Diabetes Care.

[18]  Anlin Peng,et al.  Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication , 2020, Diabetes Care.

[19]  Fang Lei,et al.  Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes , 2020, Cell Metabolism.

[20]  Avik Ray,et al.  Metformin in COVID-19: A possible role beyond diabetes , 2020, Diabetes Research and Clinical Practice.

[21]  M. Landini,et al.  COVID-19 and diabetes: Is metformin a friend or foe? , 2020, Diabetes Research and Clinical Practice.

[22]  M. Rizzo,et al.  COVID-19 and diabetes management: What should be considered? , 2020, Diabetes Research and Clinical Practice.

[23]  Zhigang Tian,et al.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[24]  Chidchamai Kewcharoenwong,et al.  Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes , 2020, Scientific Reports.

[25]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[26]  Meng Zhang,et al.  Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis , 2019, European Journal of Clinical Pharmacology.

[27]  M. McCormack,et al.  Association of Metformin Initiation and Risk of Asthma Exacerbation: A Claims-Based Cohort Study. , 2019, Annals of the American Thoracic Society.

[28]  Qingguo Lu,et al.  AMPK: a balancer of the renin–angiotensin system , 2019, Bioscience reports.

[29]  Te-Wei Ho,et al.  Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease , 2019, Respiratory Research.

[30]  Le-Xin Wang,et al.  Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies , 2019, Critical Care.

[31]  S. Atkin,et al.  A review of the anti‐inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes , 2018, Journal of cellular physiology.

[32]  A. Anzueto,et al.  Association of metformin and mortality for patients with diabetes who are hospitalized with pneumonia , 2018, Respiratory infections.

[33]  W. Symmans,et al.  Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. , 2018, Molecular cell.

[34]  G. Davey Smith,et al.  Negative control exposure studies in the presence of measurement error: implications for attempted effect estimate calibration , 2017, International journal of epidemiology.

[35]  Ian Spiers,et al.  Clinical Terminologies in the NHS: SNOMED CT and dm+d , 2017 .

[36]  S. Suissa,et al.  Prevalent new‐user cohort designs for comparative drug effect studies by time‐conditional propensity scores , 2017, Pharmacoepidemiology and drug safety.

[37]  M. Murphy,et al.  Metformin Inhibits the Production of Reactive Oxygen Species from NADH:Ubiquinone Oxidoreductase to Limit Induction of Interleukin-1β (IL-1β) and Boosts Interleukin-10 (IL-10) in Lipopolysaccharide (LPS)-activated Macrophages* , 2015, The Journal of Biological Chemistry.

[38]  R. Day,et al.  The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis , 2013, Drug Safety.

[39]  A. Bourke,et al.  Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. , 2011, Informatics in primary care.

[40]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[41]  A. Maguire,et al.  The importance of defining periods of complete mortality reporting for research using automated data from primary care , 2009, Pharmacoepidemiology and drug safety.

[42]  David S Schneider,et al.  Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases , 2008, Nature Reviews Immunology.

[43]  K. Khunti,et al.  Diabetes: glycaemic control in type 2. , 2008, BMJ clinical evidence.

[44]  W. Bilker,et al.  Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research , 2007, Pharmacoepidemiology and drug safety.

[45]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[46]  Philip J. B. Brown,et al.  Application of Information Technology: Updating the Read Codes: User-interactive Maintenance of a Dynamic Clinical Vocabulary , 1997, J. Am. Medical Informatics Assoc..